SUMO-dependent ubiquitin signaling coordinates transcriptional fitness and immune evasion in cancer
Matthias Wirth
Group leader. Cancer Therapy Resistance Group. University Medical Center Göttingen, Clinic for General, Visceral and Pediatric Surgery (Germany)
Theatre room, CiMUS
About
RNF4 links SUMOylation to ubiquitin-mediated protein control in cancer. Using machine learning, we mapped RNF4-SUMO signaling across tumors and identified CDK9 as a key therapeutic vulnerability. RNF4-SUMO signaling was also linked to tumor immunogenicity and immunotherapy response. These findings establish RNF4-SUMO signaling as a regulator of transcription and therapy response.
Bio
Matthias Wirth studied Biology at the University of Düsseldorf and obtained his PhD at the Technical University of Munich. Following postdoctoral work in Munich and at Charité Berlin, he established his independent research group in Göttingen focusing on GI cancers, tumor immunology, and epigenetic regulation. His work contributed to the identification of SUMOylation as a key regulator of tumor immune evasion and tumor immunogenicity.
Hosted by PI Carmen Rivas. Virus and cancer group, CiMUS
Certificates of attendance will be provided upon request at cimus.xestion [at] usc.es (cimus[dot]xestion[at]usc[dot]es). Please do not forget to enter your name and surname in the printout given during the lecture.